磷酸二酯酶4抑制剂在风湿免疫性疾病治疗中的应用  

An overview of phosphodiesterase 4 inhibitors in the treatment of rheumatic autoimmune diseases

作　　者：刘烨玲 郑文洁 LIU Ye-ling;ZHENG Wen-jie(Department of Rheumatology and Clinical Immunology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Key Laboratory of Rheumatology,Ministry of Education,State Key Laboratory of Difficult Severe and Rare Diseases,National Clinical Research Center for Dermatologic and Immunologic Diseases(NCRC-DID),Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院风湿免疫科,风湿免疫病学教育部重点实验室,疑难重症及罕见病国家重点实验室,国家皮肤与免疫疾病临床医学研究中心,北京100730

出　　处：《中国新药杂志》2023年第22期2240-2245,共6页Chinese Journal of New Drugs

基　　金：国家自然科学基金资助项目(82171800);中央高水平医院临床科研专项(2022-PUMCH-C-008);北京市自然科学基金资助项目(7232124)。

摘　　要：目的:综述磷酸二酯酶4(phosphodiesterase 4,PDE4)抑制剂在风湿免疫性疾病中的应用及其最新研究进展。方法:通过对近年来的相关文献和指南进行综述,探讨PDE4抑制剂在风湿免疫性疾病如银屑病关节炎、白塞综合征、类风湿关节炎、系统性红斑狼疮、强直性脊柱炎、系统性硬化症的临床疗效、安全性以及作用机制等方面的研究进展。结果:PDE4抑制剂在风湿免疫性疾病中具有显著的临床疗效,常伴随可耐受的恶心、腹泻等不良反应。结论:PDE4抑制剂是一类安全、有效的药物,在控制风湿免疫性疾病病情和改善生活质量方面发挥了重要作用,具有良好的临床应用前景。Objective:To review the application and recent research progress of phosphodiesterase 4(PDE4)inhibitors in rheumatic autoimmune diseases.Methods:Through a review of recent relevant literature and guidelines,we explored the latest research progress of PDE4 inhibitors in rheumatic autoimmune diseases such as psoriatic arthritis,Behçet’s syndrome,rheumatoid arthritis,systemic lupus erythematosus,ankylosing spondylitis,and systemic sclerosis,focusing on their clinical efficacy,safety,and mechanisms of action.Results:PDE4 inhibitors demonstrated significant clinical efficacy in rheumatic autoimmune diseases,often accompanied by manageable adverse reactions like nausea and diarrhea.Conclusion:PDE4 inhibitors are safe and effective drugs for treating rheumatic autoimmune illnesses and can improve the quality of life.They hold promising prospects for clinical applications.

关 键 词：磷酸二酯酶4抑制剂 风湿免疫性疾病 作用机制 疗效 安全性 

分 类 号：R972.6[医药卫生—药品]